Eaton Vance Management lifted its stake in shares of Pfizer (NYSE:PFE) by 2.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,679,453 shares of the biopharmaceutical company’s stock after acquiring an additional 231,247 shares during the period. Pfizer makes up about 0.8% of Eaton Vance Management’s investment portfolio, making the stock its 28th largest holding. Eaton Vance Management owned about 0.15% of Pfizer worth $314,369,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds also recently modified their holdings of the company. AMG National Trust Bank bought a new position in Pfizer in the third quarter valued at $205,000. Prudential Financial Inc. grew its position in Pfizer by 30.4% in the third quarter. Prudential Financial Inc. now owns 13,168,407 shares of the biopharmaceutical company’s stock valued at $470,113,000 after purchasing an additional 3,070,770 shares in the last quarter. Hodges Capital Management Inc. bought a new position in Pfizer in the third quarter valued at $202,000. Boston Partners grew its position in Pfizer by 18.4% in the third quarter. Boston Partners now owns 27,741,320 shares of the biopharmaceutical company’s stock valued at $990,365,000 after purchasing an additional 4,314,466 shares in the last quarter. Finally, Blackhill Capital Inc. grew its position in Pfizer by 9.8% in the third quarter. Blackhill Capital Inc. now owns 511,201 shares of the biopharmaceutical company’s stock valued at $18,250,000 after purchasing an additional 45,773 shares in the last quarter. 71.65% of the stock is owned by institutional investors.
Pfizer opened at $35.71 on Friday, according to Marketbeat. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 0.45. The stock has a market cap of $212.46 billion, a PE ratio of 13.48, a P/E/G ratio of 1.77 and a beta of 0.89. Pfizer has a 52-week low of $35.64 and a 52-week high of $35.80.
The business also recently announced a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, May 11th will be paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.81%. The ex-dividend date of this dividend is Thursday, May 10th. Pfizer’s dividend payout ratio is presently 51.32%.
A number of research firms recently weighed in on PFE. Jefferies Group reaffirmed a “neutral” rating and issued a $39.00 target price on shares of Pfizer in a research report on Monday. JPMorgan Chase set a $42.00 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Tuesday, May 8th. DZ Bank reaffirmed a “sell” rating on shares of Pfizer in a research report on Thursday, May 3rd. Morningstar set a $43.50 target price on shares of Pfizer and gave the company a “buy” rating in a research report on Wednesday, May 2nd. Finally, BMO Capital Markets decreased their target price on shares of Pfizer from $43.00 to $42.00 and set an “outperform” rating for the company in a research report on Wednesday, May 2nd. Three research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $40.08.
In other news, Director W Don Cornwell sold 1,758 shares of the firm’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $36.79, for a total transaction of $64,676.82. Following the completion of the sale, the director now owns 1,000 shares in the company, valued at approximately $36,790. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Ian C. Read sold 132,312 shares of the firm’s stock in a transaction dated Tuesday, May 1st. The stock was sold at an average price of $36.01, for a total transaction of $4,764,555.12. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 380,349 shares of company stock valued at $13,829,340. 0.06% of the stock is currently owned by corporate insiders.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.